Teleflex's Q2 performance exceeded internal expectations, driven by improving monthly revenue trends and prudent expense management. Despite a 12% revenue decline primarily due to COVID-19, the company reported adjusted earnings per share of $1.93, surpassing estimates. Excluding the estimated $130 million COVID-19 impact, Teleflex saw underlying business growth of approximately 8%, driven by continued demand for vascular access and other product categories. The company's revenue was negatively impacted by COVID-19 across Interventional Urology, Surgical, Interventional Access, Anesthesia, and OEM, but was partially offset by growth in Vascular Access. Monthly procedures improved sequentially in May and June, particularly in Interventional Urology, which has led the recovery. Teleflex has not yet fully returned to normal but is encouraged by trends into July. Despite uncertainty due to COVID-19, the company remains confident in its long-term underlying fundamentals and anticipates achieving its previous LRP financial targets of 6% to 7% revenue growth, 60% to 61% gross margin, and 30% to 31% operating margin. Teleflex has initiated a workforce reduction plan to further improve profitability, with an estimated $11 million to $13 million annual pre-tax savings once implemented.